DE69711926D1 - 3,4-disubstituierte azetidin-2-on-derivate die als cystein-proteinase regulatoren nuetzlich sind - Google Patents
3,4-disubstituierte azetidin-2-on-derivate die als cystein-proteinase regulatoren nuetzlich sindInfo
- Publication number
- DE69711926D1 DE69711926D1 DE69711926T DE69711926T DE69711926D1 DE 69711926 D1 DE69711926 D1 DE 69711926D1 DE 69711926 T DE69711926 T DE 69711926T DE 69711926 T DE69711926 T DE 69711926T DE 69711926 D1 DE69711926 D1 DE 69711926D1
- Authority
- DE
- Germany
- Prior art keywords
- derivatives
- useful
- regulators
- cystein proteinase
- azetidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2651696P | 1996-09-23 | 1996-09-23 | |
PCT/IB1997/001145 WO1998012176A1 (en) | 1996-09-23 | 1997-09-22 | 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69711926D1 true DE69711926D1 (de) | 2002-05-16 |
Family
ID=21832282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69711926T Expired - Lifetime DE69711926D1 (de) | 1996-09-23 | 1997-09-22 | 3,4-disubstituierte azetidin-2-on-derivate die als cystein-proteinase regulatoren nuetzlich sind |
Country Status (7)
Country | Link |
---|---|
US (1) | US5959123A (de) |
EP (1) | EP0950046B1 (de) |
JP (1) | JP2001503738A (de) |
AU (1) | AU4133697A (de) |
CA (1) | CA2266639A1 (de) |
DE (1) | DE69711926D1 (de) |
WO (1) | WO1998012176A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9806287D0 (en) * | 1998-03-24 | 1998-05-20 | Synphar Lab Inc | Monobactam enzyme inhibitors |
ID27137A (id) * | 1998-06-25 | 2001-03-01 | Bristol Myers Squibb Co | Penghambat-penghambat amidino dan guanidino azetidino triptase |
GB9907683D0 (en) * | 1999-04-06 | 1999-05-26 | Synphar Lab Inc | Substituted azetidin-2-ones as cysteine protease inhibitors |
GB9917909D0 (en) | 1999-07-31 | 1999-09-29 | Synphar Lab Inc | Cysteine protease inhibitors |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
WO2002070519A1 (en) * | 2001-03-05 | 2002-09-12 | Axys Pharmaceuticals, Inc. | Monobactams as cathepsin k inhibitors |
DE10148553A1 (de) * | 2001-10-01 | 2003-04-17 | Protagen Ag | Proteinaseinhibitoren zur Therapie und Diagnose von neurodegenerativen Krankheiten |
WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
NZ537952A (en) | 2002-08-08 | 2008-04-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
CA2517573C (en) * | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
WO2004089395A2 (en) * | 2003-04-01 | 2004-10-21 | Aventis Pharmaceuticals Inc. | Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease |
US20090176861A1 (en) * | 2004-01-08 | 2009-07-09 | Christopher Bayly | Cathepsin cysteine protease inhibitors |
MY139645A (en) | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
JP2007522233A (ja) * | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
WO2006089311A1 (en) * | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
AU2021306755B2 (en) * | 2020-07-04 | 2024-05-30 | Hitgen Inc. | Immunomodulator |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338538C (en) * | 1979-06-08 | 1996-08-20 | Taisuke Matsuo | 1-sulfo-2-oxoazetidine derivatives and their production |
EP0050965A1 (de) * | 1980-10-23 | 1982-05-05 | Takeda Chemical Industries, Ltd. | Beta-Lactamase inhibierende Zusammensetzung |
WO1982001873A1 (en) * | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
MX7096E (es) * | 1980-12-05 | 1987-06-19 | Takeda Chemical Industries Ltd | Metodo para preparacion de derivados de 2-oxoazetidina |
AU564150B2 (en) * | 1982-04-30 | 1987-08-06 | Takeda Chemical Industries Ltd. | 1-sulfo-2-azetidinone derivatives |
ATE197591T1 (de) * | 1995-03-31 | 2000-12-15 | Naeja Pharmaceutical Inc | 4-substituierte-3-peptidyl-azetidin-2-on-deriva e als cystein-proteinase inhibitoren |
-
1997
- 1997-09-22 AU AU41336/97A patent/AU4133697A/en not_active Abandoned
- 1997-09-22 CA CA002266639A patent/CA2266639A1/en not_active Abandoned
- 1997-09-22 US US08/935,258 patent/US5959123A/en not_active Expired - Fee Related
- 1997-09-22 DE DE69711926T patent/DE69711926D1/de not_active Expired - Lifetime
- 1997-09-22 WO PCT/IB1997/001145 patent/WO1998012176A1/en active IP Right Grant
- 1997-09-22 JP JP51444498A patent/JP2001503738A/ja active Pending
- 1997-09-22 EP EP97939136A patent/EP0950046B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2266639A1 (en) | 1998-03-26 |
WO1998012176A1 (en) | 1998-03-26 |
US5959123A (en) | 1999-09-28 |
JP2001503738A (ja) | 2001-03-21 |
EP0950046B1 (de) | 2002-04-10 |
AU4133697A (en) | 1998-04-14 |
EP0950046A1 (de) | 1999-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69711926D1 (de) | 3,4-disubstituierte azetidin-2-on-derivate die als cystein-proteinase regulatoren nuetzlich sind | |
DE69719344D1 (de) | 4-substituierte-3-(2-amino-2-cycloalkylmethyl)-acetamido-azetidin-2-on-derivate als cystein-proteinas-regulatoren | |
DE69718026T2 (de) | Fluorierte 1,4-disubstituierte piperidin-derivate | |
DE69736711D1 (de) | Substituierte 6,5-heterobicyclische-derivate | |
NO990892D0 (no) | Substituerte 6,6-hetero-bicykliske derivater | |
AP9701052A0 (en) | Substituted pyrido- or pyrimido- containing 6,6- or 6,77-bicyclic derivatives | |
ID19599A (id) | Turunan diamino-1,3,5-triazina tersubtitusi | |
EE200000041A (et) | Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid | |
EE9800300A (et) | Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid | |
DE59507222D1 (de) | Substituierte 1,2,3,4-tetrahydro-5-nitro-pyrimidine | |
NL1009260A1 (nl) | Triazine-derivaten die 2,2,6,6-tetramethyl-4-piperidylgroepen bevatten. | |
DE69915038D1 (de) | Substituierte benzoylferrocene als anionische fotoinitiatoren | |
DE69515997T2 (de) | Transkodierer | |
FR2759442B1 (fr) | Regulateur detendeur pneumatique | |
ATA163996A (de) | Schmiedemaschine | |
ATE240941T1 (de) | 1,25-dihydroxy-16,22,23-trisdehydro- cholecalciferol-derivate | |
NO993171D0 (no) | Substituerte propionylderivater | |
BR9508248A (pt) | 1,2,4,6-Tiatriazinas herbicidas | |
KR960023590U (ko) | 유, 공압 브레이커 | |
KR970044810U (ko) | 그레이트바의 탈락방지 장치 | |
FI941905A0 (fi) | Vid fartyg fastmonterbart, utloesbart oljebomsystem | |
UA25788A (uk) | Імпульсhий регулятор постійhого струму | |
SE9501770D0 (sv) | Stansverktyg | |
SE9501121D0 (sv) | Stansverktyg | |
KR970051031U (ko) | 윷놀이용 다이 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |